Table of Contents

HK J Paediatr (New Series)
Vol 24. No. 4, 2019

HK J Paediatr (New Series) 2019;24:203-215

Original Article

Comparison on Treatment Outcomes on Paediatric Acute Promyelocytic Leukaemia: ICC APL 2001 Versus HKPHOSG AML 1996 Protocol
兒童急性早幼粒細胞白血病治療效果比較-ICC APL 2001方案對比HKPHOSG AML1996方案

WYK Chan, GKS Lam, JKH Chiu, DTL Ku, KKH Ho, SY Ha; On behalf of the Hong Kong Paediatric Haematology and Oncology Study Group


Acute promyelocytic leukaemia (APL) is a biologically and clinically distinct variant of acute myeloid leukaemia (AML). Patients often presented as a medical emergency with lethal haemorrhages. Despite high early mortality rate, APL has superior event-free survival (EFS) with prompt administration of all-trans retinoic acid (ATRA). This study is a retrospective review comparing outcomes of paediatric APL patients in Hong Kong treated with the two previously adopted protocols (HKPHOSG AML 1996 versus ICC APL 2001) over past 20 years. Total 53 eligible patients were identified, 30 and 23 were treated with HKPHOSG AML 1996 and ICC APL 2001 protocol respectively. Five-year overall survival and EFS for HKPHOSG AML 1996 versus ICC APL 2001 protocol were 80% versus 82.6% and 66.7% versus 75.1% with a median follow up period of 193.4 versus 56.7 months. To conclude, local data reveals that ATRA-based therapy demonstrate better outcome than AML-based chemotherapy in treating paediatric APL patients.

急性早幼粒細胞白血病(APL)是一種生物學和臨床上有顯著不同的急性髓細胞白血病(AML)。患者常表現為一種致命性出血的臨床急症。儘管具有高早期死亡率,通過及早應用全反式維甲酸(ATRA)治療, APL具有較高無病生存率。本研究為一項回顧性分析,對過去20年香港APL病童先前採用的兩種治療方案的療效進行比較(HKPHOSG AML 1996 方案對比 ICC APL 2001方案)。符合要求病例共計53例,其中HKPHOSG AML 1996方案治療30例,ICC APL 2001方案治療23例。HKPHOSG AML 1996 方案對比ICC APL 2001方案的5年總體生存率和無病生存率分別為 80% 對比 82.6% 和66.7%對比75.1%,其平均追蹤時間為 193.4個月對比56.7個月。結論為,本地資料顯示基於ATRA的化療對APL病童的治療效果優於基於AML 的化療。

Keyword : Child; Drug therapy; Hong Kong; Leukaemia; Survival



©2020 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.